Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment

Yurttutan, Sadık; Gullu, Utku Ufuk; İpek, Sevcan

doi:10.1007/s11739-021-02663-6

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We thank Dr Yurttutan et al [1] for sharing the beneficial effect of anakinra in an 8-year-old girl with COVID-19-related multisystem inflammatory syndrome refractory to vasopressors, anticoagulation, corticosteroids, and intravenous immunoglobulin. After anakinra was added to her treatment plan at a dose of 8 mg/kg/day administered s.c. for 4 days, her cardiac functions immediately improved.…”

Section: Dear Editormentioning

confidence: 99%

“…Regarding the use of intermediate doses, the duration and tapering of anakinra in patients with COVID-19-related moderate hyperinflammation are important issues since respiratory condition stabilizes for 48-72 h after starting anakinra and then steadily improves, making it necessary to taper the dose before stopping to avoid reactivating hyperinflammation. However, in patients with severe hyperinflammation, such as the girl described by Dr Yurttutan et al [1], higher doses of anakinra are probably necessary to control SARS-CoV-2-related multisystem inflammatory syndrome and reduce mortality. In our opinion, the dose, timing of administration, duration, and tapering of anakinra for COVID-19-related hyperinflammation are essential considerations in reducing mortality and optimizing the safety/risk profile.…”

Section: Dear Editormentioning

confidence: 99%

See 1 more Smart Citation

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply

2021

View full text Add to dashboard Cite

Section: Dear Editormentioning

confidence: 99%

Section: Dear Editormentioning

confidence: 99%

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply

2021

View full text Add to dashboard Cite

Predictive value of cardiac markers in the prognosis of COVID-19 in children

Güllü

Güngör

İpek

et al. 2021

The American Journal of Emergency Medicine

View full text Add to dashboard Cite

Background and aim Occasionally, children with COVID-19 may develop arrhythmia, myocarditis, and cardiogenic shock involving multisystemic inflammatory syndrome in children (MIS-C). This study aimed to identify the laboratory parameters that may predict early cardiovascular involvement in these patients. Materials and methods Data of 320 pediatric patients, aged 0–18 years (average age, 10.46 ± 5.77 years; 156 female), with positive COVID-19 reverse transcription–polymerase chain reaction test and with cardiac biomarkers at the time of admission to the pediatric emergency department were retrospectively scanned. The age, sex, COVID-19-associated symptoms, pro-brain natriuretic peptide (proBNP), CK-MB, and troponin I levels of the patients were recorded. Results Fever was noted in 58.1% of the patients, cough in 29.7%, diarrhea in 7.8%, headache in 14.7%, sore throat in 17.8%, weakness in 17.8%, abdominal pain in 5%, loss of taste in 4.1%, loss of smell in 5.3%, nausea in 3.4%, vomiting in 3.8%, nasal discharge in 4.4%, muscle pain in 5%, and loss of appetite in 3.1%. The proBNP value ≥282 ng/L predicted the development of MIS-C with 100% sensitivity and 93% specificity [AUC: 0.985 (0.959–1), P < 0.001]; CK-MB value ≥2.95 with 80% sensitivity and 77.6% specificity [AUC: 0.792 (0.581–1), P = 0.026]; and troponin I value ≥0.03 with 60% sensitivity and 99.2% specificity [AUC: 0.794 (0.524–1)]. Conclusions Cardiac markers (proBNP and troponin I), especially proBNP, could be used to detect early diagnosis of cardiac involvement and/or MIS-C in pediatric patients with COVID-19 and to predict related morbidity and mortality.

show abstract

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment

Cited by 2 publications

References 8 publications

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply

Predictive value of cardiac markers in the prognosis of COVID-19 in children

Contact Info

Product

Resources

About